Evidence map›Paper›PMID 40483487›Full record

ArticleMolecular cancer2025

Targeting PERP promotes anti-tumor immunity in HNSCC by regulating tumor immune microenvironment and metabolic homeostasis.

Xueying Wang, Yuxi Tian, Xiaohong Wu, Yewen Zhu, Huihong Chen, Zeyao Wang, Zihan Liu, Jiaqi Tan, Zhaoyu Pan, Jiaoyan Cao and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Itaconate and its derivatives in human health and diseases.Signal transduction and targeted therapy · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Xueying Wang *Department of Otolaryngology-Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
Yuxi Tian *National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, P.R. China.
Xiaohong Wu *NHC and CAMS Key Laboratory of Molecular Probe and Targeted, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, 150001, China.
Yewen Zhu *National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, P.R. China.
Huihong ChenDepartment of Otolaryngology-Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
Zeyao WangDepartment of Surgical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, 150000, China.
Zihan LiuDepartment of Surgical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, 150000, China.
Jiaqi TanDepartment of Otolaryngology-Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
Zhaoyu PanDepartment of Otolaryngology-Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
Jiaoyan CaoNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, P.R. China.
Zhenjiang LiDepartment of Otolaryngology-Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
Xin ZhangDepartment of Otolaryngology-Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
Zhongjie ShiDepartment of Pediatrics, Wayne State University, Detroit, MI, 48201, USA.
Juncheng WangDepartment of Otolaryngology-Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China. wangjuncheng@csu.edu.cn.
Tong LiuDepartment of Surgical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, 150000, China. liutong@hrbmu.edu.cn.

Funding

Changsha Natural Science Foundation kq 2208393China Postdoctoral Science Foundation 2023M743954Chun Yan of Heilongjiang Provincial Science and Technology Department supported the planned construction project CYQN24011Harbin Medical University Cancer Hospital: Nn10 Plan Nn102024-02National Natural Science Foundation of China 82272872National Natural Science Foundation of China 82303717National Outstanding Youth Science Fund Project of National Natural Science Foundation of China 82322048Natural Science Foundation of Heilongjiang Province JQ2023H004Natural Science Foundation of Hunan Province 2023JJ40992
6 · The paper itself

Abstract

backgroundPERP may have the potential to function as an oncogene. However, the precise function, prognostic value, and predictive significance remain shrouded in ambiguity.

methodsWe conducted an in-depth analysis using pan-cancer RNA sequencing data and various online web tools to investigate the correlation between PERP and crucial clinical outcomes such as prognosis, tumor microenvironment, and tumor metabolism. In addition, we explored the tumor-promoting role of PERP and its potential mechanisms through models such as immunofluorescence staining, flow cytometry, cell proliferation assays, wound healing assays, cell migration assays, mass spectrometry analysis and isotope tracing. Further in vivo models confirmed the functional consistency of PERP across pan-cancer. Finally, we analyzed the potential of PERP as a predictive factor for immunotherapy sensitivity in a clinical cohort.

resultsPERP exhibits elevated expression in the majority of cancer types and impedes immune cell infiltration as well as immune checkpoint reactivity in pan-cancer. We confirmed that PERP can promote tumor progression by tumor cell proliferation, scratch and transwell experiments. Meanwhile, the absence of PERP restricts the flux of

conclusionsPERP represents a promising predictive/diagnostic biomarker and therapeutic target for HNSCC patients.

Indexed as

Head and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckTumor MicroenvironmentAnimalsBiomarkers, TumorCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHomeostasisHumansMicePrognosisXenograft Model Antitumor AssaysBiomarkers, TumorHead and neck squamous cell carcinomaPD1PERPPrognosisTumor microenvironment

Identifiers

PMID40483487
PMCPMC12144827

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.